Ongoing research aims to enhance the effectiveness of oncolytic virus therapy and broaden its applicability. (cancerresearch.org)
Vyriad, a biopharmaceutical company in Rochester, Minnesota, developed this technology and is led by Stephen Russell, M.D., Ph.D., a professor of molecular medicine at the Mayo Clinic and an expert in oncolytic virus therapy. (sanfordresearch.org)